Eledon Pharmaceuticals, Inc. — Key Metrics
4 years of history · ending 2016-12-31 · SEC EDGAR
Forensics
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
F-Score (Piotroski 0-9)
Working Capital Analysis
52-Week Range
Trailing Returns
ROIC vs WACC
Liquidity & Leverage Ratios
Earnings Quality (OCF/NI · FCF/NI · Sloan Accruals)
EPS (Diluted)
—
Book Value Per Share
—
Free Cash Flow Per Share
—
Cash Per Share
—
OCF Per Share
—
Return on Equity
-14137.5%
Return on Assets
-16.4%
Return on Invested Capital
-10127.8%
Current Ratio
0.30
Quick Ratio
0.30
Asset Turnover
0.00
Working Capital
$-3M
Net Current Asset Value
$-3M
Invested Capital
$-3M
OCF / Net Income
0.87
FCF / Net Income
0.87
Accruals Ratio (Sloan)
-61.2%
Net Debt
$-1M
Net Debt / EBITDA
0.22
Capex Coverage
-547.00
Tangible Common Equity
$-3M
TCE / Total Assets
-225.9%
Goodwill / Total Assets
—
NOPAT
$-4M
Cash ROIC
-12330.0%
Capex / D&A
0.26
Reinvestment Rate
0.5%
Book Value 5Y CAGR
—
Stock Price (FY-end)
$158
Market Cap
—
P/B Ratio
—
P/TB Ratio
—
Enterprise Value
—
FCF Yield
—
R&D Yield
—
Shares Variation (YoY)
—
Beta (5Y)
1.28
Cost of Equity
10.9%
52W High
$1K
52W Low
$139
Trailing Return 1Y
-88.8%
Trailing Return 5Y
—
F-Score (Piotroski)
1.00
Earnings Forecasts
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.